Repurposing disulfiram for cancer therapy via targeted nanotechnology through enhanced tumor mass penetration and disassembly
Open accessThe DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.
Abstract
Disulfiram (DSF), an FDA approved drug for the treatment of alcoholism, degrades to therapeutically active diethyldithiocarbamate (DDTC) in the body by reduction. Hereby, we developed a redox sensitive DDTC-polymer conjugate for targeted cancer therapy. It was found that the DDTC-polymer conjugate modified with a β-D-galactose receptor targeting ligand can self-assemble into LDNP nanoparticle and efficiently enter cancer cells by receptor-mediated endocytosis. Upon cellular uptake, the LDNP nanoparticle degrades and releases DDTC due to the cleavage of disulfide bonds, and subsequently forms copper (II) DDTC complex to kill a broad spectrum of cancer cells. 3D cell culture revealed that this nanoparticle shows much stronger tumor mass penetrating and destructive capacity. Furthermore, LDNP nanoparticles exhibited much greater potency in inhibiting tumor growth in a peritoneal metastatic ovarian tumor model.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Zanoni, M., Piccinini, F., Arienti, C., Zamagni, A., Santi, S., Polico, R., Bevilacqua, A., & Tesei, A. (2016) · Scientific Reports · doi:10.1038/srep19103 · Cited by 1,144 · cited 1×
“solid tumor in vivo, such as high interstitial pressure, poor vascularization, and oxygen/nutrient gradients [34].”
BackgroundProgress of drug-loaded polymeric micelles into clinical studies
Cabral, H., & Kataoka, K. (2014) · Journal of Controlled Release · doi:10.1016/j.jconrel.2014.06.042 · Cited by 837 · cited 1×
“probably due to the so called “EPR effect” as a result of leaking blood capillaries and deficiency of lymphatic system in the tumor [37].”
Background
Cited by
Selective Targeting of Cancer Cells by Copper Ionophores: An Overview
Oliveri, V. (2022) · Frontiers in Molecular Biosciences · doi:10.3389/fmolb.2022.841814 · Cited by 367
Lu, Y., Pan, Q., Gao, W., Pu, Y., Luo, K., He, B., & Gu, Z. (2022) · Biomaterials · doi:10.1016/j.biomaterials.2021.121335 · Cited by 149
Repurposing Disulfiram for Targeting of Glioblastoma Stem Cells: An In Vitro Study
Zirjacks, L., Stransky, N., Klumpp, L., Prause, L., Eckert, F., Zips, D., Schleicher, S., Handgretinger, R., Huber, S. M., & Ganser, K. (2021) · Biomolecules · doi:10.3390/biom11111561 · Cited by 16
“Moreover, surface receptor-specific targeting of disulfiram-bearing nanoparticles might enhance tumor specificity and cellular drug uptake of disulfiram therapy [71].”
BackgroundBenkő, B.-M., De Brito Parreirinha, N. S., Sebe, I., & Zelkó, R. (2026) · iScience · doi:10.1016/j.isci.2026.115441 · Cited by 2
Trim-Away in adult animals through Nano-ERASER and its application in cancer therapy
Wang, M., Wang, J., Wang, Y., Raja, M., Gupta, G., Hu, X., Shi, S., Chen, H., Fan, D., & Xu, P. (2023) · doi:10.21203/rs.3.rs-2298306/v1
Self-citation
Metadata
- Authors
- He, H., Markoutsa, E., Li, J., & Xu, P.
- Venue
- Acta Biomaterialia
- Publisher
- Elsevier BV
- Published
- 2018-03
- Volume
- 68
- Pages
- 113-124
- ISSN
- 1742-7061 (ISSN-L)
- OpenAlex
- W2776818729
- Cited by
- 69
- References
- 2
- FWCI
- 2.06
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Repurposing disulfiram for cancer therapy via targeted nanotechnology through enhanced tumor mass penetration and disassembly. https://app.cochat.ai/papers/10.1016/j.actbio.2017.12.023
- The paper
- He, H., Markoutsa, E., Li, J., & Xu, P. (2018). Repurposing disulfiram for cancer therapy via targeted nanotechnology through enhanced tumor mass penetration and disassembly. Acta Biomaterialia. https://doi.org/10.1016/j.actbio.2017.12.023
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.